SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31^st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.

Being a FTSE 100 company is exciting at one level but can be very boring at another, as anybody can see by looking at the Footsie’s inability to get anywhere close to its peak levels well over three years ago, unlike the FTSE 250.  Still, at least the FTSE 100 is ahead of the FTSE AIM index compared to the dot-com bubble which ended in early 2000.  What a mad world that was, even if it meant the first five full years of my investment management career usefully showed a bunch of busts and booms.

SkinBioTherapeutics (SBTX) has announced results for its year ended 30^th June 2021 emphasising “transformational” progress. So what is this?

SkinBioTherapeutics (SBTX) has announced it has commercially launched its probiotic food supplement to help alleviate the symptoms associated with psoriasis, AxisBiotix-Ps.

As things stand at 69p, we are 289% ahead on this share tip but there is much more to come. SkinBioTherapeutics (SBTX) has announced its probiotic food supplement to help alleviate the symptoms of psoriasis, AxisBiotix-Ps, is to launch on 29^th October, following highly positive results from its consumer study in May and key commercialisation activities since.

SkinBioTherapeutics (SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30^th June year-end cash totalled £4.6 million. Sounds good.

SkinBioTherapeutics (SBTX) has announced the results of the AxisBiotix-PsT consumer study of patients suffering from psoriasis and it says that it will now be seeking regulatory approval for the product as a food supplement in parallel in the UK, US and Europe… targeting a commercial launch of theAxisBiotix-Ps™ product in Q4 2021”.  Do the maths! This is going to be massive.

Notwithstanding the lock-in shenanigans with Optibiotix (OPTI) discussed HERE, I am more bullish than ever. The results from Skinbiotherapeutics (SBTX) for the six months to 31 December 2020 came out on Monday. I apologise for the delayed update but I needed to ponder a while. What we read a few days ago was just excellent. Hence this upgrade.

Shares in this company, where I am a loyal shareholder, raced ahead to 33p on Friday.  The excitement was driven largely by a false rumour and in part, methinks, on a rumour that is true. This morning I had it confirmed that the false rumour was, er, false.

Skinbiotherapeutics (SBTX) boss Stuart Ashman until today held zero shares in the company. And he told us all that it had enough cash to last it until the end of next year at least.  And so now there is a £4 million placing and £500,000 open offer at 16p.  Mr Ashman can you see why I might be annoyed?

Very excited shareholder Tom Winnifrith writes: On 26 May 2020, Steve and I tipped SkinBiotherapeutics (SBTX) at a 17.75p offer and at up to 20p with a target price of 30p. News last week suggests that, notwithstanding this company wasting a few grand a month employing the biggest knobhead in Christendom to do its PR, we were more than a tad conservative and the shares now trade at 22p-23.5p and are still dirt cheap.

SkinBioTherapeutics (SBTX) has updated that it is “very pleased with the progress that the company has been able to make during these most exceptional times”, particularly including “several months ahead of schedule, Winclove has now been able to successfully combine and formulate the blend as a probiotic food supplement, to be known as AxisBiotix ™Ps”...

“The boards of Croda Europe and Plant Impact are pleased to announce that they have reached agreement on the terms of a unanimous recommended cash offer” for Plant Impact (PIM)… of 10.57p per share. Hmmm, “pleased to announce” hey…

Hello Share Smashers. I can claim to be an expert in chemicals. Well, not really, though I hold a GCE in chemistry which shocked my old teacher when he saw the list of successful students. Which leads me to look at Croda (CRDA) - a chemicals company based within aping distance of my birth town, Doncaster.

Yesterday's bull call of the day which came in the form of Vodafone (VOD), was apart from the technical highlights, also a possible bid target situation. 

According to the excellent ShareProphets website search functionality it is over 140 days since I wrote a piece titled ‘Update on 8 share tips’.  In the spirit of continued openness and accountability, how are these eight tips looking and what would be my view now?